Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957242 · ClinicalTrials.gov registry record · Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
NCT00957242 is a Phase 3 study that was terminated before completion, run by Duke University. The registered enrollment target is 145 participants.
The verdict
NCT00957242, a Phase 3 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than 10% in forced vital capacity (FVC) from baseline.
Interventions
- DRUG placebo
- DRUG warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957242
The ClinicalTrials.gov registry entry for NCT00957242 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00957242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957242 about?
NCT00957242 is a clinical study titled "AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis". This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death,...
What is the current status of trial NCT00957242?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2009-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00957242?
The interventions under investigation include: placebo (DRUG), warfarin (DRUG).
Who is sponsoring clinical trial NCT00957242?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.